Stock RVNC REVANCE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.4 USD +3.34% Intraday chart for Revance Therapeutics, Inc. -10.05% -61.32%
Apr. 26 AbbVie raises annual profit forecast on strong Skyrizi sales RE
Apr. 12 Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting CI

Business Summary

Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

Number of employees: 597

Sales per Business

USD in Million2022Weight2023Weight Delta
Product
94.8 %
126 94.7 % 222 94.8 % +76.62%
Service
5.2 %
7 5.3 % 12 5.2 % +75.24%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
133 100.0 % 234 100.0 % +76.55%

Managers

Managers TitleAgeSince
Mark Foley CEO
 Chief Executive Officer 58 17-09-04
Tobin Schilke DFI
 Director of Finance/CFO 49 18-11-04
Azita Nejad CTO
 Chief Tech/Sci/R&D Officer - 13-12-31
Conor Gallagher CTO
 Chief Tech/Sci/R&D Officer - 18-05-08
David Hollander CTO
 Chief Tech/Sci/R&D Officer 50 22-10-16
Jessica Serra IRC
 Investor Relations Contact - -
Erica Jordan PRN
 Corporate Officer/Principal - -
Dwight Moxie LAW
 General Counsel 48 20-01-31

Members of the board

Members of the board TitleAgeSince
Angus Russell CHM
 Chairman 68 11-02-28
Mark Foley CEO
 Chief Executive Officer 58 17-09-04
Jill Beraud BRD
 Director/Board Member 63 19-06-03
Julian Gangolli BRD
 Director/Board Member 66 16-06-30
Carey Kolaja BRD
 Director/Board Member 51 21-02-28
Olivia Ware BRD
 Director/Board Member 67 21-03-05
Vladimir Coric BRD
 Director/Board Member 53 23-02-28
Christian Nolet BRD
 Director/Board Member 67 19-07-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 104,215,614 95,385,648 ( 91.53 %) 0 91.53 %

Shareholders

NameEquities%Valuation
Capital Research & Management Co. (World Investors)
11.46 %
11,939,076 11.46 % 59 M $
BlackRock Advisors LLC
6.743 %
7,027,276 6.743 % 35 M $
Teoxane SA
6.286 %
6,550,800 6.286 % 32 M $
GIC Pte Ltd. (Investment Management)
5.590 %
5,825,881 5.590 % 29 M $
Palo Alto Investors LP
5.025 %
5,237,284 5.025 % 26 M $
Vanguard Fiduciary Trust Co.
4.865 %
5,069,625 4.865 % 25 M $
Fiduciary Trust Company International
4.557 %
4,749,539 4.557 % 23 M $
JPMorgan Investment Management, Inc.
4.437 %
4,624,521 4.437 % 23 M $
POLAR CAPITAL HOLDINGS PLC
3.041 %
3,169,239 3.041 % 16 M $
STATE STREET CORPORATION
2.420 %
2,521,693 2.420 % 12 M $

Company contact information

Revance Therapeutics, Inc.

1222 Demonbreun Street Suite 2000

37203, Nashville

+615 724 7755

http://www.revance.com
address Revance Therapeutics, Inc.(RVNC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Ratings for Revance Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
3.4 USD
Average target price
16.33 USD
Spread / Average Target
+380.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
REVANCE THERAPEUTICS, INC. Stock Revance Therapeutics, Inc.
-61.32% 354M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. RVNC Stock
  4. Company Revance Therapeutics, Inc.